Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
26
|
pubmed:dateCreated |
1992-9-10
|
pubmed:abstractText |
Four trials including 11,266 sheep were conducted in South Africa to evaluate the efficacy of the systemic parasiticide ivermectin against field outbreaks of sheep scab (Psoroptes ovis) when two doses of approximately 200 micrograms/kg were administered subcutaneously seven days apart (days 0 and 7). As sheep scab is a notifiable disease in South Africa, it was not possible to include an untreated control group. The prevalence of clinically affected animals in the four treated flocks varied from 0.4 per cent to 99 per cent before the two treatments. After the treatments, there were no signs of active clinical infection in any of the sheep between days 28 and 30, or at subsequent examinations. P ovis mites were recovered from scrapings from 114 of 127 indicator sheep before the treatment but no mites were recovered from them between days 28 and 30 or 42 and 58 after the treatments.
|
pubmed:commentsCorrections | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
0042-4900
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
27
|
pubmed:volume |
130
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
572-4
|
pubmed:dateRevised |
2003-11-14
|
pubmed:meshHeading |
pubmed-meshheading:1496769-Animals,
pubmed-meshheading:1496769-Disease Outbreaks,
pubmed-meshheading:1496769-Female,
pubmed-meshheading:1496769-Ivermectin,
pubmed-meshheading:1496769-Male,
pubmed-meshheading:1496769-Mite Infestations,
pubmed-meshheading:1496769-Mites,
pubmed-meshheading:1496769-Sheep,
pubmed-meshheading:1496769-Sheep Diseases,
pubmed-meshheading:1496769-Skin,
pubmed-meshheading:1496769-South Africa
|
pubmed:year |
1992
|
pubmed:articleTitle |
Treatment and control of sheep scab (Psoroptes ovis) with ivermectin under field conditions in South Africa.
|
pubmed:affiliation |
Merck Sharp & Dohme Research Laboratories, Rahway, NJ 07065.
|
pubmed:publicationType |
Journal Article
|